Shares of CinCor Pharma, Inc. (NASDAQ:CINC – Get Rating) have received an average rating of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $45.83.

A number of equities analysts recently weighed in on CINC shares. Oppenheimer lowered shares of CinCor Pharma from an "outperform" rating to a "market perform" rating in a research report on Monday, November 28th. Piper Sandler reduced their target price on shares of CinCor Pharma from $73.00 to $53.00 in a research note on Monday, November 28th. The Goldman Sachs Group began coverage on shares of CinCor Pharma in a research note on Friday, October 28th. They set a "buy" rating and a $67.00 target price on the stock. Morgan Stanley lifted their target price on shares of CinCor Pharma from $22.00 to $30.00 and gave the stock an "equal weight" rating in a research note on Tuesday, January 10th. Finally, Barclays downgraded shares of CinCor Pharma from an "overweight" rating to an "equal weight" rating and lifted their target price for the stock from $22.00 to $31.00 in a research note on Thursday, January 12th.

CinCor Pharma Stock Performance

CINC opened at $28.80 on Friday. CinCor Pharma has a fifty-two week low of $10.53 and a fifty-two week high of $43.15. The company has a fifty day moving average of $18.38 and a two-hundred day moving average of $26.05. The stock has a market capitalization of $1.26 billion and a price-to-earnings ratio of -1.67.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. American International Group Inc. boosted its holdings in shares of CinCor Pharma by 8.9% in the 2nd quarter. American International Group Inc. now owns 6,272 shares of the company's stock valued at $118,000 after buying an additional 511 shares in the last quarter. Amalgamated Bank boosted its stake in CinCor Pharma by 27.0% during the 3rd quarter. Amalgamated Bank now owns 2,670 shares of the company's stock worth $88,000 after purchasing an additional 567 shares during the period. Bartlett & Co. LLC acquired a new stake in CinCor Pharma during the 3rd quarter worth $26,000. Walleye Capital LLC boosted its stake in CinCor Pharma by 3.8% during the 2nd quarter. Walleye Capital LLC now owns 29,323 shares of the company's stock worth $552,000 after purchasing an additional 1,073 shares during the period. Finally, Credit Suisse AG boosted its stake in CinCor Pharma by 18.1% during the 3rd quarter. Credit Suisse AG now owns 12,043 shares of the company's stock worth $395,000 after purchasing an additional 1,850 shares during the period. Institutional investors and hedge funds own 99.15% of the company's stock.

CinCor Pharma Company Profile

(Get Rating)

CinCor Pharma, Inc, a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases.

Further Reading

• Get a free copy of the StockNews.com research report on CinCor Pharma (CINC)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for CinCor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CinCor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.